
Cagrilintide
Cagrilintide (NN9838)
Cagrilintide is a synthetic, long-acting analog of amylin, a 37-amino-acid peptide hormone co-secreted with insulin by pancreatic beta cells. Native amylin is short-lived and prone to forming insoluble fibrils, which limits its use in research. Cagrilintide was engineered to address both problems: amino-acid substitutions reduce fibrillation, and N-terminal acylation with a fatty diacid promotes albumin binding for an extended half-life.
The design of cagrilintide was described by Kruse and colleagues in the Journal of Medicinal Chemistry in 2021. It is used in the laboratory to study amylin receptor pharmacology, which is unusual because amylin receptors are formed by the calcitonin receptor paired with receptor activity-modifying proteins (RAMPs).
Cagrilintide is an investigational compound and is not approved by the FDA. PhysIQ Peptides supplies it as a lyophilized powder, third-party tested for purity and identity, for in vitro and laboratory research use only.
Choose how to buy
You save $2.50 every reship · ≈ $30.42 saved per year
Auto-delivered • Skip or cancel anytime • Never run out
Your first order ships at the regular price. Every reship after that is 5% off. Pause, change the interval, or cancel anytime.
- Purity
- ≥99%
- Form
- Powder (lyophilized)
- CAS Number
- 1415456-99-3
- Molecular Weight
- 4409.0 g/mol
- Available sizes
- 5mg
Mechanism of Action
Cagrilintide acts as a non-selective agonist at amylin receptors (AMY1–3, formed by the calcitonin receptor with RAMP1, 2 or 3) and at the calcitonin receptor itself. These are Gs-coupled receptors that raise intracellular cAMP. In preclinical models, amylin receptor signaling in the hindbrain is studied for its role in gastric emptying and satiety pathways.
Research Areas
- ●Amylin receptor (AMY1–3) pharmacology
- ●Calcitonin receptor and RAMP biology
- ●Peptide fibrillation and stability studies
- ●Long-acting peptide analog design
Selected References
- Kruse T, et al. J Med Chem. 2021;64(15):11183-11194.




